Head to head
Oracle vs Microsoft
Side-by-side on the measures that matter, with a plain-English read. Full detail: ORCL · MSFT
ORCL
Oracle
141.40+4.59%
1-year price shape — -52% over the period
Quant Rating E · 5/100
vs
MSFT
Microsoft
535.07+2.38%
1-year price shape — +3% over the period
Quant Rating C · 42/100
1-year performance, rebased to 100
Microsoft edges it on the scoreable measures. Microsoft has the highest Quant Rating (42); Microsoft has done best over the past year (+3%); Microsoft earns the most per share.
| ORCL | MSFT | |
|---|---|---|
| Snapshot | ||
| Sector | Software - Infrastructure | Software - Infrastructure |
| Last price | 141.40 | 535.07 |
| Change today | +4.59% | +2.38% |
| 1-year return | -51.9% | +3.3% |
| Market cap | $427.56B | $3.97T |
| 52-week range | 114.08 – 318.28 | 348.54 – 549.20 |
| Valuation | ||
| P/E (TTM) | 22.16 | 29.81 |
| P/E percentile, own 5-yr range | 6th | 30th |
| P/B | 6.92 | 8.98 |
| Dividend yield | 1.41% | 0.67% |
| Profitability & growth | ||
| EPS (TTM) | 5.83 | 17.95 |
| Net profit (TTM) | $17.63B | $133.29B |
| Revenue (TTM) | $71.78B | $331.84B |
| Revenue growth (YoY) | +29.6% | +17.7% |
| Gross margin | 64.0% | 67.9% |
| Operating margin | 34.2% | 46.8% |
| Net margin | 26.1% | 40.3% |
| Free cash flow (TTM) | $-28.72B | $66.99B |
| Ownership & sentiment | ||
| Institutional ownership | 43.2% | 75.2% |
| Insider activity (12mo) | 30 buy / 20 sell | 31 buy / 16 sell |
| Short interest (% of float) | 1.6% | 0.8% |
| Analyst consensus | 82% buy / 15% hold / 3% sell (33) | 100% buy (34) |
| Analyst price target | $243 (+72%) | $594 (+11%) |
| StockVane view | ||
| StockVane Quant Rating | E (5) | C (42) |
| Company | ||
| Employees | 141,000 | 223,000 |
| Founded | 1977 | 1975 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.